1nfy › Citations

Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket.

Maignan S, Guilloteau JP, Choi-Sledeski YM, Becker MR, Ewing WR, Pauls HW, Spada AP, Mikol V
J Med Chem 46 685-90 (2003)
Related entries: 1nfu, 1nfw, 1nfx

Cited: 56 times
EuropePMC logo PMID: 12593649

Abstract

The structures of the noncovalent complex of human factor Xa (fXa) with four non-peptide inhibitors containing a central sulfonylpiperazinone scaffold have been determined to about 2.1 A resolution. Highly potent fXa inhibitors containing both neutral groups such as chlorobenzothiophene or chlorothiophene and basic groups such as benzamidine were shown to interact in the S1 pocket through the neutral group whereas the S4 pocket is occupied by the basic moiety. The scaffold comprising the sulfonyl keto piperazine moiety might play a pivotal role in the orientation of substituents, since there is a strong hydrogen bond between Gly219 of fXa and the carbonyl oxygen of the piperazine. This unique "reverse" binding mode is heretofore unreported in fXa and shows that electrostatic interactions in the S1 subsite are not an absolute requirement to maintain high affinity. Selectivity against other serine proteases can be readily explained in light of these structural results. It has opened up new prospects for designing fXa inhibitors with increased oral bioavailability.

Articles - 1nfy mentioned but not cited (4)

  1. Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. Abel R, Young T, Farid R, Berne BJ, Friesner RA. J. Am. Chem. Soc. 130 2817-2831 (2008)
  2. Inclusion of multiple fragment types in the site identification by ligand competitive saturation (SILCS) approach. Raman EP, Yu W, Lakkaraju SK, MacKerell AD. J Chem Inf Model 53 3384-3398 (2013)
  3. Factor Xa active site substrate specificity with substrate phage display and computational molecular modeling. Hsu HJ, Tsai KC, Sun YK, Chang HJ, Huang YJ, Yu HM, Lin CH, Mao SS, Yang AS. J. Biol. Chem. 283 12343-12353 (2008)
  4. Molecular Docking, Computational, and Antithrombotic Studies of Novel 1,3,4-Oxadiazole Derivatives. Batool M, Tajammal A, Farhat F, Verpoort F, Khattak ZAK, Mehr-un-Nisa, Shahid M, Ahmad HA, Munawar MA, Zia-Ur-Rehman M, Asim Raza Basra M. Int J Mol Sci 19 (2018)


Reviews citing this publication (5)

  1. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. Nat Rev Drug Discov 10 61-75 (2011)
  2. Developments in factor Xa inhibitors for the treatment of thromboembolic disorders. Lee YK, Player MR. Med Res Rev 31 202-283 (2011)
  3. Novel factor Xa inhibitors: a patent review. de Candia M, Lopopolo G, Altomare C. Expert Opin Ther Pat 19 1535-1580 (2009)
  4. The application of bioisosteres in drug design for novel drug discovery: focusing on acid protease inhibitors. Hamada Y, Kiso Y. Expert Opin Drug Discov 7 903-922 (2012)
  5. [Significance of quantum chemical interactions for medicinal science and design of β-secretase inhibitors]. Hamada Y. Yakugaku Zasshi 133 1113-1120 (2013)

Articles citing this publication (47)

  1. Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity. Matter H, Nazaré M, Güssregen S, Will DW, Schreuder H, Bauer A, Urmann M, Ritter K, Wagner M, Wehner V. Angew. Chem. Int. Ed. Engl. 48 2911-2916 (2009)
  2. Structure-activity studies in a family of beta-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction. Fasan R, Dias RL, Moehle K, Zerbe O, Obrecht D, Mittl PR, Grütter MG, Robinson JA. Chembiochem 7 515-526 (2006)
  3. Contribution of explicit solvent effects to the binding affinity of small-molecule inhibitors in blood coagulation factor serine proteases. Abel R, Salam NK, Shelley J, Farid R, Friesner RA, Sherman W. ChemMedChem 6 1049-1066 (2011)
  4. Cl-pi interactions in protein-ligand complexes. Imai YN, Inoue Y, Nakanishi I, Kitaura K. Protein Sci. 17 1129-1137 (2008)
  5. Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand. Schärer K, Morgenthaler M, Paulini R, Obst-Sander U, Banner DW, Schlatter D, Benz J, Stihle M, Diederich F. Angew. Chem. Int. Ed. Engl. 44 4400-4404 (2005)
  6. More than a simple lipophilic contact: a detailed thermodynamic analysis of nonbasic residues in the s1 pocket of thrombin. Baum B, Mohamed M, Zayed M, Gerlach C, Heine A, Hangauer D, Klebe G. J. Mol. Biol. 390 56-69 (2009)
  7. Thermodynamics of Water in an Enzyme Active Site: Grid-Based Hydration Analysis of Coagulation Factor Xa. Nguyen CN, Cruz A, Gilson MK, Kurtzman T. J Chem Theory Comput 10 2769-2780 (2014)
  8. Cation-pi interactions at the active site of factor Xa: dramatic enhancement upon stepwise N-alkylation of ammonium ions. Salonen LM, Bucher C, Banner DW, Haap W, Mary JL, Benz J, Kuster O, Seiler P, Schweizer WB, Diederich F. Angew. Chem. Int. Ed. Engl. 48 811-814 (2009)
  9. Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering. Muthas D, Sabnis YA, Lundborg M, Karlén A. J. Mol. Graph. Model. 26 1237-1251 (2008)
  10. The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor. Kohrt JT, Bigge CF, Bryant JW, Casimiro-Garcia A, Chi L, Cody WL, Dahring T, Dudley DA, Filipski KJ, Haarer S, Heemstra R, Janiczek N, Narasimhan L, McClanahan T, Peterson JT, Sahasrabudhe V, Schaum R, Van Huis CA, Welch KM, Zhang E, Leadley RJ, Edmunds JJ. Chem Biol Drug Des 70 100-112 (2007)
  11. Molecular recognition at the active site of factor Xa: cation-π interactions, stacking on planar peptide surfaces, and replacement of structural water. Salonen LM, Holland MC, Kaib PS, Haap W, Benz J, Mary JL, Kuster O, Schweizer WB, Banner DW, Diederich F. Chemistry 18 213-222 (2012)
  12. Solvation thermodynamic mapping of molecular surfaces in AmberTools: GIST. Ramsey S, Nguyen C, Salomon-Ferrer R, Walker RC, Gilson MK, Kurtzman T. J Comput Chem 37 2029-2037 (2016)
  13. Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification. Komoriya S, Kobayashi S, Osanai K, Yoshino T, Nagata T, Haginoya N, Nakamoto Y, Mochizuki A, Nagahara T, Suzuki M, Shimada T, Watanabe K, Isobe Y, Furugoori T. Bioorg. Med. Chem. 14 1309-1330 (2006)
  14. Dispersion dominated halogen-π interactions: energies and locations of minima. Wallnoefer HG, Fox T, Liedl KR, Tautermann CS. Phys Chem Chem Phys 12 14941-14949 (2010)
  15. Amide-pi interactions between formamide and benzene. Imai YN, Inoue Y, Nakanishi I, Kitaura K. J Comput Chem 30 2267-2276 (2009)
  16. Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes. Nazaré M, Matter H, Will DW, Wagner M, Urmann M, Czech J, Schreuder H, Bauer A, Ritter K, Wehner V. Angew. Chem. Int. Ed. Engl. 51 905-911 (2012)
  17. Arylsulfonamides: a study of the relationship between activity and conformational preferences for a series of factor Xa inhibitors. Senger S, Convery MA, Chan C, Watson NS. Bioorg. Med. Chem. Lett. 16 5731-5735 (2006)
  18. Polyphenol compounds belonging to flavonoids inhibit activity of coagulation factor X. Bijak M, Ponczek MB, Nowak P. Int. J. Biol. Macromol. 65 129-135 (2014)
  19. Protein pharmacophore selection using hydration-site analysis. Hu B, Lill MA. J Chem Inf Model 52 1046-1060 (2012)
  20. Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa. Kochanny MJ, Adler M, Ewing J, Griedel BD, Ho E, Karanjawala R, Lee W, Lentz D, Liang AM, Morrissey MM, Phillips GB, Post J, Sacchi KL, Sakata ST, Subramanyam B, Vergona R, Walters J, White KA, Whitlow M, Ye B, Zhao Z, Shaw KJ. Bioorg. Med. Chem. 15 2127-2146 (2007)
  21. Design, synthesis, and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units. Haginoya N, Kobayashi S, Komoriya S, Yoshino T, Nagata T, Hirokawa Y, Nagahara T. Bioorg. Med. Chem. 12 5579-5586 (2004)
  22. Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of betaII tryptase. Levell J, Astles P, Eastwood P, Cairns J, Houille O, Aldous S, Merriman G, Whiteley B, Pribish J, Czekaj M, Liang G, Maignan S, Guilloteau JP, Dupuy A, Davidson J, Harrison T, Morley A, Watson S, Fenton G, McCarthy C, Romano J, Mathew R, Engers D, Gardyan M, Sides K, Kwong J, Tsay J, Rebello S, Shen L, Wang J, Luo Y, Giardino O, Lim HK, Smith K, Pauls H. Bioorg. Med. Chem. 13 2859-2872 (2005)
  23. SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa. Qiao JX, Chang CH, Cheney DL, Morin PE, Wang GZ, King SR, Wang TC, Rendina AR, Luettgen JM, Knabb RM, Wexler RR, Lam PY. Bioorg. Med. Chem. Lett. 17 4419-4427 (2007)
  24. New series of 6-substituted coumarin derivatives as effective factor Xa inhibitors: synthesis, in vivo antithrombotic evaluation and molecular docking. Amin KM, Abdel Gawad NM, Abdel Rahman DE, El Ashry MK. Bioorg. Chem. 52 31-43 (2014)
  25. The discovery of glycine and related amino acid-based factor Xa inhibitors. Kohrt JT, Filipski KJ, Cody WL, Bigge CF, La F, Welch K, Dahring T, Bryant JW, Leonard D, Bolton G, Narasimhan L, Zhang E, Peterson JT, Haarer S, Sahasrabudhe V, Janiczek N, Desiraju S, Hena M, Fiakpui C, Saraswat N, Sharma R, Sun S, Maiti SN, Leadley R, Edmunds JJ. Bioorg. Med. Chem. 14 4379-4392 (2006)
  26. Computational tools for the analysis and visualization of multiple protein-ligand complexes. O'Brien SE, Brown DG, Mills JE, Phillips C, Morris G. J. Mol. Graph. Model. 24 186-194 (2005)
  27. Ligand scaffold hopping combining 3D maximal substructure search and molecular similarity. Quintus F, Sperandio O, Grynberg J, Petitjean M, Tuffery P. BMC Bioinformatics 10 245 (2009)
  28. Design, synthesis and characterization of a novel class of coumarin-based inhibitors of inducible nitric oxide synthase. Jackson SA, Sahni S, Lee L, Luo Y, Nieduzak TR, Liang G, Chiang Y, Collar N, Fink D, He W, Laoui A, Merrill J, Boffey R, Crackett P, Rees B, Wong M, Guilloteau JP, Mathieu M, Rebello SS. Bioorg. Med. Chem. 13 2723-2739 (2005)
  29. Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand. Nazaré M, Matter H, Klingler O, Al-Obeidi F, Schreuder H, Zoller G, Czech J, Lorenz M, Dudda A, Peyman A, Nestler HP, Urmann M, Bauer A, Laux V, Wehner V, Will DW. Bioorg. Med. Chem. Lett. 14 2801-2805 (2004)
  30. Letter Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors. Van Huis CA, Bigge CF, Casimiro-Garcia A, Cody WL, Dudley DA, Filipski KJ, Heemstra RJ, Kohrt JT, Narasimhan LS, Schaum RP, Zhang E, Bryant JW, Haarer S, Janiczek N, Leadley RJ, McClanahan T, Thomas Peterson J, Welch KM, Edmunds JJ. Chem Biol Drug Des 69 444-450 (2007)
  31. Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold. Al-Horani RA, Mehta AY, Desai UR. Eur J Med Chem 54 771-783 (2012)
  32. Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa. Lopopolo G, Fiorella F, de Candia M, Nicolotti O, Martel S, Carrupt PA, Altomare C. Eur J Pharm Sci 42 180-191 (2011)
  33. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors. Imaeda Y, Miyawaki T, Sakamoto H, Itoh F, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K. Bioorg. Med. Chem. 16 2243-2260 (2008)
  34. Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents. Nazaré M, Essrich M, Will DW, Matter H, Ritter K, Urmann M, Bauer A, Schreuder H, Dudda A, Czech J, Lorenz M, Laux V, Wehner V. Bioorg. Med. Chem. Lett. 14 4191-4195 (2004)
  35. Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand. Nazaré M, Essrich M, Will DW, Matter H, Ritter K, Urmann M, Bauer A, Schreuder H, Czech J, Lorenz M, Laux V, Wehner V. Bioorg. Med. Chem. Lett. 14 4197-4201 (2004)
  36. Sulfonamidolactam inhibitors of coagulation factor Xa. Smallheer JM, Wang S, Laws ML, Nakajima S, Hu Z, Han W, Jacobson I, Luettgen JM, Rossi KA, Rendina AR, Knabb RM, Wexler RR, Lam PY, Quan ML. Bioorg. Med. Chem. Lett. 18 2428-2433 (2008)
  37. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors. Shi Y, Sitkoff D, Zhang J, Han W, Hu Z, Stein PD, Wang Y, Kennedy LJ, O'Connor SP, Ahmad S, Liu EC, Seiler SM, Lam PY, Robl JA, Macor JE, Atwal KS, Zahler R. Bioorg. Med. Chem. Lett. 17 5952-5958 (2007)
  38. Facile synthesis of structurally diverse 5-oxopiperazine-2-carboxylates as dipeptide mimics and templates. Limbach M, Lygin AV, Korotkov VS, Es-Sayed M, de Meijere A. Org. Biomol. Chem. 7 3338-3342 (2009)
  39. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation. Wang W, Yuan J, Fu X, Meng F, Zhang S, Xu W, Xu Y, Huang C. Molecules 21 491 (2016)
  40. Application of molecular connectivity and electro-topological indices in quantitative structure-activity analysis of pyrazole derivatives as inhibitors of factor Xa and thrombin. Krishnasamy C, Raghuraman A, Kier LB, Desai UR. Chem. Biodivers. 5 2609-2620 (2008)
  41. Effective Estimation of Ligand-Binding Affinity Using Biased Sampling Method. Ngo ST, Vu KB, Bui LM, Vu VV. ACS Omega 4 3887-3893 (2019)
  42. Molecular dynamics simulations of Factor Xa: insight into conformational transition of its binding subsites. Singh N, Briggs JM. Biopolymers 89 1104-1113 (2008)
  43. Pyrazole-Based Thrombin Inhibitors with a Serine-Trapping Mechanism of Action: Synthesis and Biological Activity. Dunker C, Imberg L, Siutkina AI, Erbacher C, Daniliuc CG, Karst U, Kalinin DV. Pharmaceuticals (Basel) 15 1340 (2022)
  44. Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders. Roehrig S, Ackerstaff J, Jiménez Núñez E, Teller H, Ellerbrock P, Meier K, Heitmeier S, Tersteegen A, Stampfuss J, Lang D, Schlemmer KH, Schaefer M, Gericke KM, Kinzel T, Meibom D, Schmidt M, Gerdes C, Follmann M, Hillisch A. J Med Chem 66 12203-12224 (2023)
  45. Molecular Dynamics Simulation Study of the Selective Inhibition of Coagulation Factor IXa over Factor Xa. Yoon HJ, Kundu S, Wu S. Molecules 28 6909 (2023)
  46. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors. Huang C, Wang W, Li Y, Zhang S, Meng F, Xu W, Yuan J, Chen L. Oncotarget 8 37186-37199 (2017)
  47. Unexpected Dynamic Binding May Rescue the Binding Affinity of Rivaroxaban in a Mutant of Coagulation Factor X. Zhang ZL, Chen C, Qu SY, Ding Q, Xu Q. Front Mol Biosci 9 877170 (2022)


Quick links